Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock

Key Points

• Director Karimah Es Sabar sold 7,529 shares on April 2 at an average of $32.00 for $240,928, and also sold 53,735 (Apr 1) and 61,265 (Mar 31) shares — a total of 122,529 shares for roughly $3.76 million; the April 2 transaction was executed under a pre-arranged Rule 10b5-1 trading plan and cut her stake by about 50%.
• Capricor stock traded near $32.11 with a market cap of $1.85 billion and a 12‑month range of $4.30–$40.37, and Wall Street holds a Moderate Buy consensus with an average price target of $46.09 while several firms recently raised targets into the $50–$63 range.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) Director Karimah Es Sabar sold 7,529 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the transaction, the director directly owned 7,529 shares in the company, valued at approximately $240,928. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05.
• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.17, for a total value of $1,848,365.05.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock remained flat at $32.11 during trading on Friday. The stock had a trading volume of 1,225,548 shares, compared to its average volume of 1,798,446. The company has a market capitalization of $1.85 billion, a PE ratio of -14.21 and a beta of 0.48. The business has a 50 day simple moving average of $27.20 and a two-hundred day simple moving average of $18.83. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). As a group, sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CAPR. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, December 4th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, January 11th. Piper Sandler restated an "overweight" rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, B. Riley Financial raised their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a "buy" rating in a research note on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at $28,000. Parkside Financial Bank & Trust bought a new stake in Capricor Therapeutics in the 3rd quarter worth $36,000. Russell Investments Group Ltd. increased its position in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company's stock valued at $37,000 after acquiring an additional 2,786 shares during the period. ACT Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $43,000. Finally, GoalVest Advisory LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at about $59,000. Institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.